CClinicalTrials.gg
CompletedNCT05349487SPEAKFREEUpdated Feb 3, 2025

SpeakFree Heat and Moisture Exchanger (HME)

An interventional study of SpeakFree HME Hands Free Valve and Digital Occlusion in Laryngeal Cancer and Laryngectomy, sponsored by University of Miami. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by University of Miami · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 8 months ago, and no results have been posted to the registry.
Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to evaluate the new Blom-Singer SpeakFree disposable hands free valve heat and moisture exchanger (HME). The investigators will compare the SpeakFree to other modalities of stomal occlusion (digital occlusion and digital depression of an HME) for patients who communicate with a voice prosthesis as determined by patient preference and satisfaction. In addition, the investigators will compare the SpeakFree to other modalities of stomal occlusion as determined by objective measures of speech and voice parameters (maximum phonation time, syllables per breath, minimum/maximum phonation pressures, and a clinician rating of voice quality using a visual analog scale).

02

Conditions studied

  • Laryngeal Cancer
  • Laryngectomy

Browse trials for

Keywords

  • Stoma
  • Voice Prosthesis
  • Total Laryngectomy
  • Heat and Moisture Exchanger (HME)
03

In context

Laryngeal Neoplasms

244 studies on the registry are indexed under Laryngeal Neoplasms; 63 are open to participants now.

This study's enrollment of 18 is below the median of 44 across 181 interventional studies indexed under Laryngeal Neoplasms.

Browse Laryngeal Neoplasms studies →

Lead sponsor

University of Miami is the lead sponsor of 820 studies on the registry; 161 are open to participants now.

Of its 111 completed or terminated interventional studies of FDA-regulated products, 93 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Participants who have undergone a total laryngectomy who have and use a voice prosthesis as their primary form of communication for at least 3 months prior to study enrollment.
  • Participants must have had at least 2 voice prosthesis management visits from a speech pathologist at the University of Miami prior to study enrollment.
  • Participants must have fully healed suture lines.
  • Participants must demonstrate fluent tracheoesophageal speech (i.e., maximum phonation time of at least 5 seconds during 3 consecutive trials)
  • Current HME use for a minimum of 1 month
  • Participants willing to complete the survey and provide a signed Informed Consent Form
  • Males and non-pregnant females over the age of 18

Exclusion criteria

Exclusion Criteria:

  • Participants who do not have a voice prosthesis.
  • Participants who have dysarthria.
  • Participants who are currently receiving treatment for head and neck cancer.
  • Participants who have an underlying neurologic condition potentially impacting speech.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    SpeakFree Hands Free Heat Moisture Exchanger (HEM) Valve Group

    Participants will be fitted to use a hand free HME device over their stoma in order to communicate with a voice prosthesis for one month. The participants will also serve as their own control performing voicing and speech tasks using digital occlusion and digital depression HME.

    Device: SpeakFree HME Hands Free Valve · Other: Digital Occlusion · Device: Digital Depression HME

Interventions

  • DeviceSpeakFree HME Hands Free Valve

    A voice prosthesis, SpeakFree HME Hands Free Valve, achieved with creation of a tracheoesophageal puncture will be placed over the stoma for 1 month.

  • OtherDigital Occlusion

    Using participant's own fingers, they will be putting their fingers over the stoma.

  • DeviceDigital Depression HME

    A digital handheld press-down HME will be placed over stoma.

06

What researchers measure

Primary outcomes

  1. Satisfaction as measured by VAS

    Patient preference and satisfaction will be measured using a visual Analog Scale (VAS) ranging in score from 1-10 with a higher score indicating greater satisfaction with the device.

    Time frame: Up to 1 month

  2. Voice Quality: Patient Rating

    Voice Quality will be measured using a visual Analog Scale ranging in score from 1-10 with a higher score indicating that the patient feels their voice quality is better with the device.

    Time frame: Up to 1 month

Secondary outcomes

  1. Change in Maximum Phonation Time

    Maximum phonation time (MPT) is a clinical measurement of the longest time a person can phonate a vowel in seconds.

    Time frame: Baseline, 1 month

  2. Change in Syllables Per Breath

    Participants' number of syllables per breath while reading a standardized reading passage will be measured and reported.

    Time frame: Baseline, 1 month

  3. Pressure Needed to Phonate

    Minimal and maximal pressures will be reported using a manometer while the participant counts from 1 to 15.

    Time frame: Baseline

  4. Change in Voice Quality: Clinician Rating

    The clinician will rate participant's voice quality using VAS. VAS has a total score ranging from 1 to 10 with the higher score indicating that the clinician feels that participant's voice quality is better with the device.

    Time frame: Baseline, 1 month

07

Study locations

1 site
  • University of Miami
    Miami, Florida 33136, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05349487
Lead sponsor
University of Miami
Responsible party
Mario Alberto Landera, SLP.D (Associate Professor of Clinical, University of Miami) — Principal investigator
First posted
Apr 27, 2022
Start date
Jun 28, 2022
Primary completion
Jan 30, 2025
Completion
Jan 30, 2025
Last update
Feb 3, 2025

Study contacts

Mario A Landera, SLP.D.
principal investigator · University of Miami

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion